— Know what they know.
Not Investment Advice

IRTC NASDAQ

iRhythm Technologies, Inc.
1W: +8.7% 1M: +9.9% 3M: +1.1% YTD: -29.4% 1Y: -31.5% 3Y: +50.6% 5Y: +74.8%
$123.75
+1.82 (+1.49%)
 
Weekly Expected Move ±5.0%
$109 $115 $121 $127 $134
NASDAQ · Healthcare · Medical - Devices · Tech Score Buy · Power 70 · $4.1B mcap · 30M float · 1.89% daily turnover · Short 64% of daily vol
Credit Risk of going bust: lower than 61% of companies Debt: 15.1% of company value Bonds: $39.8M held by 21 funds → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.78 (down 99%), iRhythm Technologies, Inc. would be worth roughly what it owes.
Total debt $727.3M against a stock market value of $4.08B.
Distance to default 6.31 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $327.1M (short-term plus half of long-term), stock volatility 43.6%; Altman Z 3.02. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Smart Money Score
Bullish 75
Insider+$0.1M
Congress—
ETF Holdings—
Key Statistics
Market Cap$4.1B
52W Range100.7-212
Volume380,383
Avg Volume571,548
Beta1.32
Dividend—
Analyst Ratings
18 Buy 3 Hold 0 Sell
Consensus Buy
Company Info
CEOQuentin S. Blackford
Employees2,400
SectorHealthcare
IndustryMedical - Devices
IPO Date2016-10-20
699 8th Street
San Francisco, CA 94103
US
415 632 5700
About iRhythm Technologies, Inc.

iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.

Recent Insider Trades

NameTypeSharesPriceDate
Wilson Daniel G. S-Sale 773 $121.83 2026-09-02
Blackford Quentin S. S-Sale 26,859 $124.65 2026-08-10
Murphy Patrick Micha S-Sale 7,093 $124.65 2026-08-10
Patterson Chad S-Sale 7,093 $124.65 2026-08-10
Shrishrimal Sumi S-Sale 5,372 $124.65 2026-08-10

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms